Grants for Small businesses - Science and Technology

This grant provides funding opportunities for a wide range of organizations, including universities and businesses, to advance manufacturing technologies, with a particular encouragement for participation from historically black colleges and universities and minority institutions.

The Louis Stokes Alliances for Minority Participation (LSAMP) program invests in the Nation's colleges and universities to aid student success to create a new generation of STEM discoverers for the national STEM enterprise. The program takes a comprehensive approach to the STEM Learning Ecosystem to impact STEM student development and retention. LSAMP is an alliance-based program, whereby a group of institutions of higher education (IHEs) work together to diversify the nation's science, technology, engineering, and mathematics (STEM) workforce by increasing the number of STEM baccalaureate and graduate degrees awarded to persons from LSAMP populations. LSAMP populations are defined as persons from groups underrepresented in the STEM enterprise: Blacks and African-Americans, Hispanic and Latino Americans, American Indians, Alaska Natives, Native Hawaiians, and Pacific Islanders. The LSAMP program provides funding to alliances that implement comprehensive, evidence-based, innovative, and sustained strategies that ultimately result in the graduation of well-prepared, highly competitive students from LSAMP populations who pursue graduate studies or careers in STEM, while also supporting knowledge generation, knowledge utilization, assessment of program impacts, dissemination activities and dissemination of scholarly research into the field. Projects supported by the LSAMP program include: --Alliance Development Grants (ADG) support the conceptualization and development of new B2B and new SPIO alliances. (New) --Bridge-to-the-Baccalaureate (B2B) alliances facilitate the successful transfer of students from LSAMP populations to four-year institutions in pursuit of STEM baccalaureate degrees. --STEM Pathways Implementation-Only (SPIO) alliances are designed for new and reconstituted alliances. These projects focus on building and strengthening strategies and approaches to assist Institutions of Higher Education (IHEs) increase STEM baccalaureate degrees to LSAMP populations and facilitate entry into STEM graduate degree programs. --STEM Pathways Research Alliances (SPRA) are designed for well-established alliances. These projects serve as models of excellence in STEM broadening participation by (1) steadily increasing STEM baccalaureate degrees to LSAMP populations and facilitating entry into STEM graduate degree programs; (2) producing and disseminating new scholarly research on the broadening participation of LSAMP populations (or underrepresented and underserved populations in STEM disciplines and the nation's STEM workforce) and, (3) holistically assess the state of institutionalization and sustainability of the alliance. --Bridge to STEM Graduate Degrees in National Priorities (BD-Master's) projects support cohorts of six graduate students pursuing a M. S. degree in STEM national priority areas, providing financial support (stipends and cost of education) and support to help develop and maintain academic and research skills that enable participants to successfully persist in STEM graduate degree programs at Master's comprehensive-degree producing institutions only. (New) --Bridge to STEM Graduate Degrees in National Priorities (BD-Doctoral) projects support cohorts of twelve graduate students pursuing a Ph.D. degree in STEM national priority areas, providing financial support (stipends and cost of education) and support to help develop and maintain academic and research skills that enable participants to successfully persist in STEM doctoral degree programs. --STEM Networking Incentives and Engagement (NETWORKS) projects provide support to incentivize the creation and participation of LSAMP populations in STEM networks. (New)

The NISTs Accelerating Federal Technology Transfer (AFTT) Program is seeking applications from eligible applicants for activities to help promote, educate, and facilitate federal technology transfer. Under the AFTT Program, members of the Federal Laboratory Consortiums (FLC) Executive Board, including NIST, will collaborate with the awardee on the development of outreach and educational programs, tools, and best practices that will enhance the ability of the academic and private sectors to engage with Federal laboratories in technology transfer and research commercialization. Specifically, the awardee will collaborate with the FLCs Executive Board, including NIST, in the areas of technology transfer and research commercialization by: developing the necessary tools and services to promote the utilization of Federal intellectual property, user facilities, and other R resources by non-federal partners; creating a suitable education and training infrastructure in technology transfer for the relevant stakeholders; and engaging industry, academic, and state and local government communities to facilitate access to federal R collaborations and federal technology transfer opportunities on both a regional and a national level.

This program provides competitive funding for community organizations and local governments to build or improve public facilities that support work, education, and health monitoring in response to the COVID-19 pandemic.

Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors from different institutions, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community. Since its inception, the Academys ECIs have presented at and chaired sessions for ovarian cancer-specific symposia and served on symposia review committees. They have also served as peer reviewers for the Department of Defense (DOD) OCRP and other funding agencies.Pre-Application (Preproposal) Submission Deadline: 5:00 p.m. Eastern time (ET), May 14, 2024 • Invitation to Submit an Application: June 17, 2024 • Application Submission Deadline: 11:59 p.m. ET, August 6, 2024 • End of Application Verification Period: 5:00 p.m. ET, August 9, 2024 • Peer Review: October 2024 • Programmatic Review: December 2024

To implement a project aimed at advancing U.S. foreign policy and national security priorities by supporting initiatives that make decision-making structures and processes in fragile, conflict, or crisis-affected contexts more reflective of and responsive to the needs and perspectives of partner states to ensure strategic trade control systems meet international standards and by engaging on bilateral, regional and multilateral levels with foreign governments to aid in the establishment of independent capabilities to regulate transfers of weapons of mass destruction, WMD-related items, conventional arms, and related dual-use items, and to detect, interdict, investigate, and prosecute illicit transfers of such items.

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY24 PRMRP Topic Areas and one of the FY24 PRMRP Strategic Goals. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families. The product(s) to be developed under the PRMRP TTDA mechanism may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A knowledge product is a non-materiel product that addresses an identified need in a topic area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)The Technology/Therapeutic Development Award is not intended for basic research. Applicants generating preliminary data, basic research, performing high-risk/high-gain studies should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.

The FY24 PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY24 PRMRP Topic Areas and FY24 PRMRP Strategic Goals. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale phase 1 to phase 3 trials to determine efficacy in relevant patient populations.Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Funding from this award mechanism must support a clinical trial. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.

The FY24 PRMRP Impact Award supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from the real-world environment, to foster clinical applicability. The intent of the Impact Award is to translate the fundamental understanding of underlying mechanisms toward practical applications that have the potential for major near-term impact on patients affected by one of the diseases and conditions included in the FY24 PRMRP Topic Areas.Proposed research should refine mature concepts and ideas into translatable solutions with a view toward evaluating technical feasibility of promising new pharmacological agents, knowledge products, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance, and/or emerging approaches and technologies. The FY24 PRMRP Impact Award is not intended to support basic research.For the purposes of this funding opportunity, basic research is defined as exploratory science directed toward greater knowledge or understanding of the fundamental aspects of phenomena or outcomes, without specific applications toward process and products. Examples include, but are not limited to, high-risk/high-gain approaches, mechanistic studies, and preliminary data generation/validation. Applicants seeking funding for research that meets this definition should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern time (ET), May 13, 2024

The PRMRP Investigator-Initiated Research Award (IIRA) supports fundamental research studies that will make an important contribution toward research, patient care, and/or quality of life for a disease or condition related to one of the FY24 PRMRP Topic Areas and one of the FY24 PRMRP Strategic Goals. This award mechanism is intended to support basic research that is exploratory in nature and seeks to further or validate preliminary findings for short- or long-term impact. Research projects may focus on any stage of basic laboratory research, ranging from fundamental research for the generation of knowledge, hypothesis, or models, to expansion of mature data.The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinicians first-hand knowledge of patients, or anecdotal data. The project should include a well-formulated testable hypothesis based on existing evidence. Applications must include relevant preliminary data that support the rationale and feasibility for the proposed study. These data may be unpublished or from the published literature.This award mechanism is not intended to support translational research. Applicants seeking funding for projects that have progressed beyond the realm of basic research should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.

The FY24 PRMRP Lifestyle and Behavioral Health Interventions Research Award (LBIRA) supports clinical research and/or clinical trials using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance, and public health. Applications are required to address and provide a solution to one of the congressionally directed FY24 PRMRP Topic Areas and FY24 PRMRP Strategic Goals.The overall intent of the FY24 PRMRP LBIRA mechanism is to promote evidence-based and patient-centered approaches to improve health and/or disease-related outcomes and enhance the patient experience in defined populations. Research ideas may include, but are not limited to: Development and testing for efficacy of lifestyle interventions and symptom management approaches to minimize disease risk and maximize quality of life. Studies to investigate the impact of prevention, diagnostics, treatment, or health care delivery approaches on health outcomes. Studies to assess the relationship(s) between behavioral, cognitive, and/or social functioning in relation to disease or condition initiation, progression, detection, treatment, and rehabilitation. Studies to examine and improve quality of life or decision-making. Population-focused studies to identify behavioral and lifestyle predictors of disease and/or disease progression.Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern time (ET), May 13, 2024

The PRMRP Discovery Award is intended to support innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research but must be novel and must be based on a strong scientific rationale and a well-developed study design and plan of analysis. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation or product development. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.This award is not intended to support/validate ongoing research and inclusion of preliminary data is not allowed. Inclusion of preliminary data other than serendipitous finding is not consistent with the exploratory nature of this award. Applicants seeking funding for research to further an existing research project should consider one of the other FY24 PRMRP program announcements being offered. For information about these award mechanisms, see Section II.A.1, FY24 PRMRP Research Development Pipeline.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models), and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. If cell lines or animals are to be used, a clear justification should be provided for the choice of proposed cell line(s) or animal model(s).

The purpose of this document is to advise the public that the NOAA RESTORE Science Program is soliciting proposals for projects of five years in duration with the option for a five year, non-competitive renewal award for high-performing projects. This announcement invites proposals that request funding for partnerships that include researchers, resource managers, and other interested parties to conduct a collaborative research project that will identify, track, understand, or predict trends and variability in the Gulf of Mexicos natural resources and the abiotic and biotic factors driving those trends. Funding is contingent upon the availability of funds in the Gulf Coast Restoration Trust Fund. It is anticipated that final recommendations for funding under this Announcement will be made in June 2025, and that projects funded under this Announcement will have a October 1, 2025 start date. Total funding for this competition will be approximately $17.5 million over five years and approximately six projects may be funded. The minimum individual award amount is approximately $1 million over five years (an average of $200,000 per year) and the maximum individual award amount is approximately $4 million over five years (an average of $800,000 per year). An additional $21 million may be available for five year, non-competitive renewals for high performing projects. Information regarding this Announcement, including webinars and additional background information, is available on the Science Programs website (https://restoreactscienceprogram.noaa.gov/funding-opportunities/ffo-2025).The NOAA RESTORE Science Program encourages applicants and awardees to support the principles of diversity, equity, and inclusion when writing their proposals and performing their work. Promoting diversity, inclusion, and equity improves the creativity, productivity, and vitality of the research and management communities and leads to more robust natural resource management decisions.Electronic Access: The NOAA RESTORE Science Program website (http://restoreactscienceprogram.noaa.gov/) furnishes supplementary information. Full proposals should be submitted electronically through Grants.gov (http://www.grants.gov).

The OCRP seeks to advance ovarian cancer research through development of early-career investigators. The OCRP Ovarian Cancer Academy (OCA) is a unique, interactive environment providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty to move ovarian cancer research into a new frontier. The overarching goal of the OCA is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment to enhance quality and expand quantity of the ovarian cancer research field.

To implement a project aimed at advancing U.S. foreign policy and national security priorities outlined in the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act of 2022 (Div. A, P.L. 117-167). The Act established a new International Technology Security and Innovation Fund (ITSI Fund) to to support the development and adoption of secure semiconductors, [and] semiconductor supply chains with the goal to make the global semiconductor supply chain more resilient, diversified, and secure.

The FY24 OCRP Clinical Trial Translational Endpoints Research Award intends to support correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Correlative studies may be associated with a past, ongoing, or future clinical trial in order to associate various factors (genetic, DOD FY24 Ovarian Cancer Clinical Trial Translational Endpoints Research Award 4biochemical, environmental and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. The proposed research may be hypothesis testing or may be designed to generate new hypotheses to be tested in follow-up clinical research. The award may not be used to directly support a clinical trial.

The FY24 VRP MCRA is intended to support patient-oriented vision injury research and develop research expertise of highly motivated military or civilian clinicians in training. Research supported by the MCRA can be a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study.Each MCRA must be led by an established clinician or Ph.D. clinical scientist who will serve as Principal Investigator (PI) of the award. Key personnel must include a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program). The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. The clinician in training will conduct the proposed research under the mentorship of the PI, with support from supporting personnel as appropriate. While additional junior scientists or clinicians may participate in the research, only one clinician in training may be designated as mentee. A Letter of Organizational Support and Mentee Eligibility, signed by the Department Chair or appropriate organization official, and a Letter of Commitment, signed by the mentee, should be submitted as part of Attachment 2: Supporting Documentation.For the purposes of this award mechanism, clinical research is defined as research conducted with human subjects or research on material of human origin, such as tissues or specimens or data obtained from human subjects. Documentation of Institutional Review Board (IRB)/ Ethics Committee (EC) approval or exemption by December 1, 2024, is required for an MCRA application to be considered for funding. See Attachment 2: Supporting Documentation for additional detail.The MCRA may not be used to conduct preclinical research (including animal research) or clinical trials.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Studies that retrospectively analyze data generated from previously conducted clinical trial(s) are not considered a clinical trial.